Company / Return on Equity (ROE)
Pacira BioSciences, Inc. Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
1.0%
FY2025
5-year range
-12.8% / 4.8%
FY2021-FY2025
Trend
+107.9%
vs FY2024
Sector context
#49 of 190
Health Care
What the data says
At 1.0%, Pacira BioSciences, Inc.'s return on equity (roe) ranks #49 of 190 in the Health Care sector. Return on Equity (ROE) has fluctuated over the past 10 years, ranging from -17.3% in FY2018 to 4.8% in FY2023.
Based on SEC 10-K filings.
1.0% in FY2025 with a 5-year CAGR of +1.2%.
Declined from 4.8% to 1.0% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -1.0pp
- 5-Year Change
- +1.2pp
- 10-Year Change
- -
Sector benchmark
#49 of 190 in Health CareTop 26% of 190This company 1.0% Sector average -50.4%
▼
+102.0% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 107.9% year-over-year.
- Currently 51.4pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2023.
- Lowest return on equity (roe) in the period was in FY2018.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Negative profit margin: -14.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 1.0% | +107.9% |
| FY2024 | -12.8% | -365.4% |
| FY2023 | 4.8% | +135.1% |
| FY2022 | 2.1% | +166.1% |
| FY2021 | -3.1% | -1966.7% |
| FY2020 | -0.1% | +99.0% |
| FY2019 | -15.3% | +12.0% |
| FY2018 | -17.3% | -2138.8% |
| FY2017 | 0.9% | +104.9% |
| FY2016 | -17.3% | -2138.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026